439 related articles for article (PubMed ID: 29368638)
1. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J; Armstrong AJ; Friedlander TW; Kim W; Pal SK; George DJ; Zhang T
J Immunother Cancer; 2018 Jan; 6(1):4. PubMed ID: 29368638
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
Kammerer-Jacquet SF; Deleuze A; Saout J; Mathieu R; Laguerre B; Verhoest G; Dugay F; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987368
[TBL] [Abstract][Full Text] [Related]
3. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
7. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
9. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
11. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Brown LC; Zhu J; Labriola MK; Wu Y; Cheris S; Liu X; Perkinson K; Su Z; McCall S; Huang J; Foo WC; Gupta RT; Armstrong AJ; George DJ; Harrison MR; Zhang T
Clin Genitourin Cancer; 2020 Dec; 18(6):509-513. PubMed ID: 32482566
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
18. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
Bedke J; Stühler V; Todenhöfer T; Stenzl A
Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
